865838-26-2

Basic information

• Product Name: RX-3117
• Synonyms: RX-3117;4-Amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)-2-cyclopenten-1-yl]-2(1H)-pyrimidinone;RX-3117 (TV-1360)
• CAS NO: 865838-26-2
• Molecular Formula: C10H12FN3O4
• Molecular Weight: 257.2183832
• Mol File: 865838-26-2.mol

Chemical Properties

• Boiling Point: 516.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.82±0.1 g/cm3(Predicted)
• PKA: 12.88±0.70(Predicted)
• CAS DataBase Reference: RX-3117(CAS DataBase Reference)
• NIST Chemistry Reference: RX-3117(865838-26-2)
• EPA Substance Registry System: RX-3117(865838-26-2)

Safety Data

• Hazardous Substances Data: 865838-26-2(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
RX-3117 is used as an anticancer agent for its ability to selectively target and kill tumor cells. Its unique mechanism of action involves conversion to its active form by a specific enzyme found in cancer cells, thereby minimizing damage to healthy cells and reducing side effects.
Used in Drug Resistance Overcoming:
RX-3117 is used as a therapy to combat drug-resistant tumors. Its effectiveness against a broad range of tumor types, including those resistant to conventional chemotherapy, makes it a valuable tool in overcoming resistance and improving treatment outcomes for cancer patients.
Used in Cancer Treatment Research:
RX-3117 is utilized in clinical trials as a subject of investigation for its potential as a novel anticancer therapy. Ongoing research aims to further evaluate its safety, efficacy, and optimal application in cancer treatment, with the goal of expanding treatment options for patients with various types of cancer.
Used in Pharmaceutical Development:
In the pharmaceutical industry, RX-3117 serves as a key compound in the development of new cancer treatments. Its innovative properties and demonstrated effectiveness in preclinical studies make it a promising candidate for further research and potential incorporation into future cancer therapeutics.

Upstream product

• 865838-20-6 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl)pyrimidine-2,4(1H,3H)-dione 
• 1067238-44-1 (2R,3S,4S)-3,4-(O-isopropylidenedioxy)-2-vinyl-hexan-5-en-1,2-diol 
• 1067238-45-2 (3R,4S,5S)-3-(benzyloxymethyl)-1,6-dien-4,5-(O-isopropylidenedioxy)-heptan-3-ol 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 
• 532-20-7 D-Ribose 
• 117307-62-7 (3aR,6aR)-6-Benzyloxymethyl-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-one 
• 96690-02-7 5-O-(tert-butyldiphenylsilyl)-2,3-O-isopropylidene-D-ribofuranose 
• 491578-02-0 (3aS,4R,6aR)-6-(benzyloxymethyl)-5-fluoro-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 491577-99-2 (3aR,6aR)-6-benzyloxymethyl-5-iodo-2,2-dimethyl-3a,6a-dihydro-cyclopenta[1,3]dioxol-4-one 
• 491578-00-8 (3aS,4R,6aR)-6-benzyloxymethyl-5-iodo-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-ol 
• 491578-01-9 ((3aR,4R,6aR)-6-(benzyloxymethyl)-5-iodo-2,2-dimethyl-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)(tert-butyl)diphenylsilane 
• 681853-99-6 (1R,4S,5S)-1-(benzyloxymethyl)-2-en-4,5-(O-isopropylidenedioxy)-cyclopentan-1-ol 
• 681853-93-0 (1R)-(-)-1-[(4R,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-2-(tert-butyldiphenylsilyloxy)ethan-1-ol 
• 681853-95-2 (-)-1-[(4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-2-(tert-butyldiphenylsilyloxy)ethan-1-one 

Relevant articles and documents

Design, synthesis and anticancer activity of fluorocyclopentenyl-purines and – pyrimidines

Based on the potent anticancer activity of 6′-fluorocyclopentenyl-cytosine 2b in phase IIa clinical trials for the treatment of gemcitabine-resistant pancreatic cancer, we carried out a systematic structure-activity relationship study of 6′-fluorocyclopen

FLUOROCYCLOPENTENYLCYTOSINE USES AND PROCESSES OF PREPARATION

The disclosed subject matter provides methods using and kits comprising a compound of formula (I): Formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one o

PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R, 5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE

Processes for the preparation of 4-amino-1-((1 S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-lH-pyrimidin-2-one (13, RX-3117) and its intermediates are described.

Fluorocyclopentenyl-cytosine with broad spectrum and potent antitumor activity

On the basis of the potent biological activity of cyclopentenyl- pyrimidines, fluorocyclopentenyl-pyrimidines were designed and synthesized from d-ribose. Among these, the cytosine derivative 5a showed highly potent antigrowth effects in a broad range of

Synthesis and antitumor activity of fluorocyclopentenyl-pyrimidines

Synthesis of fluorocyclopentenyl pyrimidine nucleosides 6-9 was enantiopurely accomplished employing oxidative rearrangement, RCM reaction and electrophilic fluorination starting from D-ribose. Cytosine analog 8 was found to exhibit significant anticancer

Nucleoside derivatives and therapeutic uses therof

The present invention relates to nucleoside derivatives represented by general formulas I and II, their synthetic methods and their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperprolifera